**Trial Timeframe**

Data collected: June 01, 2021 – June 07, 2021

Data collected for: December 15, 2020 – May 15, 2021 (5 mos)

**Groups**:

Unvaccinated – positive lab COVID-19 testing with no record of immunization against COVID-19 or first-dose vaccination after symptom onset

Partially Vaccinated – positive lab COVID-19 testing and symptom onset after single dose of mRNA (Pfizer, Moderna) vaccine or, <14 days after second dose of mRNA vaccine or <14 days after administration of single dose of viral vector vaccine (Johnson & Johnson)

Fully Vaccinated – positive lab COVID-19 testing and symptom onset >14 days since administration of second dose of mRNA vaccine, or >14 days since administration of viral vector vaccine (Johnson & Johnson)

**Country of enrollment**:

United States – all participants

**Primary Outcome**

This is what they are primarily looking at in the study

Participants presented to the Emergency Center or Hospitalized for COVID-19

**Secondary Outcome**

This is what they are secondarily looking at in the study.

Data for secondary outcome in partially vaccinated and fully vaccinated individuals is lacking as of this study; not enough numbers to look at.

Patients with severe infection; ICU admission, mechanical ventilation, or in-hospital mortality

**Extracorporeal Membrane Oxygenation (ECMO)**